Decoy CEO Rick Pierce Joins June 11 hVIVO Capital Markets Day in London
Updated
Updated · BioSpace · Jun 8
Decoy CEO Rick Pierce Joins June 11 hVIVO Capital Markets Day in London
2 articles · Updated · BioSpace · Jun 8
Summary
June 11 is the date Decoy Therapeutics CEO Rick Pierce will speak at hVIVO’s Capital Markets Day in Canary Wharf, London, alongside executives from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies.
The half-day event will center on early clinical development, with discussion of how specialist partners and human challenge trials can speed better-informed decisions on moving novel therapeutics toward the clinic.
Decoy said that approach fits its strategy for Designable Multi-Antivirals, developed on its AI-enabled IMP3ACT platform to shorten the path from concept to clinic.
A pan-coronavirus program leads Decoy’s pipeline, which the company said is targeting entry into the clinic in 2027; attendance is limited and a recording will be posted on hVIVO’s website.